Cargando…

Evaluation of in vitro Penetration of Fluticasone Propionate from MP-AzeFlu and Fluticasone Propionate Nasal Spray Through EpiAirway™606 Tissues Using Vertical Diffusion Cells

PURPOSE: Most patients with allergic rhinitis (AR) have moderate-to-severe disease, requiring complete and prompt relief when symptoms occur. The time course of fluticasone propionate (FP) penetration into nasal tissues after intranasal administration is not well characterized. The goal of this proo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berger, William E, Bachert, Claus, Allara, Robert, Koltun, Arkady, Kopietz, Ferdinand, Maus, Joachim G, D’Addio, Alexander D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266522/ https://www.ncbi.nlm.nih.gov/pubmed/32547111 http://dx.doi.org/10.2147/JAA.S238421

Ejemplares similares

MP‐AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children
por: Berger, W., et al.
Publicado: (2016)

Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers
por: Roca-Ferrer, Jordi, et al.
Publicado: (2018)

MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis
por: van Weissenbruch, Ranny, et al.
Publicado: (2020)

Superior effect of MP‐AzeFlu compared to monotherapy with fluticasone propionate or azelastine on GILZ, MKP‐1 and TTP anti‐inflammatory gene expression in healthy and inflamed upper airway mucosa
por: Vicens‐Artés, Sònia, et al.
Publicado: (2022)

The Comparative Bioavailability of Fluticasone and Azelastine Delivered as a Single Fixed Dose Combination (MP-AzeFlu) in Comparison to Two Different Formulations of Azelastine and Fluticasone Propionate Following Intranasal Administration in Healthy Chinese Volunteers
por: Qi, Wenyuan, et al.
Publicado: (2023)

A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US
por: Prenner, Bruce M
Publicado: (2016)

A Clinical Study to Assess the Efficacy and Safety of MP-AzeFlu Nasal Spray in Comparison to Commercially Available Azelastine Hydrochloride and Fluticasone Propionate Nasal Sprays in Chinese Volunteers with Allergic Rhinitis
por: Zhou, Bing, et al.
Publicado: (2023)

Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma
por: Price, David, et al.
Publicado: (2020)

Evaluation of Fluticasone Propionate and Fluticasone Propionate/Salmeterol Combination on Exercise in Pediatric and Adolescent Patients with Asthma
por: Murray, John J, et al.
Publicado: (2011)

Fluticasone furoate/fluticasone propionate – different drugs with different properties
por: Biggadike, Keith
Publicado: (2011)

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
por: Houghton, Catherine M, et al.
Publicado: (2007)

Effects of MP-AzeFlu enhanced by activation of bitter taste receptor TAS2R
por: Ekstedt, Sandra, et al.
Publicado: (2020)

Effect of MP‐AzeFlu compared to monotherapy on COX‐2, PGE(2), and EP2 gene expression in upper airway mucosa
por: Vicens‐Artes, Sonia, et al.
Publicado: (2022)

Fluticasone Propionate Liposomes for Pulmonary Delivery
por: Nirale, N. M., et al.
Publicado: (2009)

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
por: Kariyawasam, Harsha H, et al.
Publicado: (2010)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
por: Jin, Xiaofen, et al.
Publicado: (2020)

Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care
por: De Jong, Hilda J.I., et al.
Publicado: (2020)

The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis
por: Guan, Renzheng, et al.
Publicado: (2019)

An efficacy and safety evaluation of montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: a meta-analysis
por: Wei, Zhengbo, et al.
Publicado: (2023)

Degradation rates and products of fluticasone propionate in alkaline solutions
por: Tokumura, Tadakazu, et al.
Publicado: (2017)

Fluticasone-propionate: COVID-19 infection: case report
Publicado: (2020)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma
por: Pavord, Ian, et al.
Publicado: (2007)

Real‐life effectiveness of MP‐AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy
por: Kaulsay, Ranbir, et al.
Publicado: (2018)

Real-Life Effectiveness of MP-AzeFlu (Dymista(®)) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale
por: Stjärne, Pär, et al.
Publicado: (2023)

The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device
por: Tashkin, Donald P., et al.
Publicado: (2021)

Budesonide and fluticasone propionate differentially affect the airway epithelial barrier
por: Heijink, I. H., et al.
Publicado: (2016)

Fluticasone propionate and increased risk of pneumonia in COPD: is it PAFR-dependent?
por: Sohal, Sukhwinder Singh
Publicado: (2017)

Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function
por: Belchamber, Kylie BR, et al.
Publicado: (2018)

A multicenter, prospective, noninterventional study in a Norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with MP-AzeFlu
por: Dollner, Ralph, et al.
Publicado: (2017)

Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease
por: Koser, Andras, et al.
Publicado: (2010)

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
por: Yawn, Barbara P, et al.
Publicado: (2010)

Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella Pneumoniae in mice
por: Patterson, Craig M, et al.
Publicado: (2012)

Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
por: Papi, A, et al.
Publicado: (2017)

No dose effect observed with chronic fluticasone propionate on growth velocity in children
por: Lee, Laurie A., et al.
Publicado: (2020)

Beneficial Immunomodulatory Effects of Fluticasone Propionate in Chlamydia pneumoniae-Infected Mice
por: Paróczai, Dóra, et al.
Publicado: (2021)

Dexamethasone/salmeterol/fluticasone-propionate: Invasive pulmonary Aspergillosis: case report
Publicado: (2021)

Fluticasone Furoate, a Novel Inhaled Corticosteroid, Demonstrates Prolonged Lung Absorption Kinetics in Man Compared with Inhaled Fluticasone Propionate
por: Allen, Ann, et al.
Publicado: (2012)

In vitro effects of fluticasone propionate on IL-13 production by mitogen-stimulated lymphocytes.
por: Di Lorenzo, Gabriele, et al.
Publicado: (2002)

Lost in the Mist: Acute Adrenal Crisis Following Intranasal Fluticasone Propionate Overuse
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2010)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6fafog267ma05jfrpk7hurih2f